JP2005531589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531589A5 JP2005531589A5 JP2004508106A JP2004508106A JP2005531589A5 JP 2005531589 A5 JP2005531589 A5 JP 2005531589A5 JP 2004508106 A JP2004508106 A JP 2004508106A JP 2004508106 A JP2004508106 A JP 2004508106A JP 2005531589 A5 JP2005531589 A5 JP 2005531589A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- inhibitors
- pharmaceutically acceptable
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 18
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 18
- 239000002777 nucleoside Substances 0.000 claims description 18
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229960000311 ritonavir Drugs 0.000 claims description 10
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 10
- -1 sarcitabine Chemical compound 0.000 claims description 10
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 9
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 9
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 102000014150 Interferons Human genes 0.000 claims description 9
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 9
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 9
- 229960004748 abacavir Drugs 0.000 claims description 9
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 9
- 229960004150 aciclovir Drugs 0.000 claims description 9
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 9
- 229960001830 amprenavir Drugs 0.000 claims description 9
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 9
- 229960005319 delavirdine Drugs 0.000 claims description 9
- 229960002656 didanosine Drugs 0.000 claims description 9
- 229960003804 efavirenz Drugs 0.000 claims description 9
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 9
- 229960002963 ganciclovir Drugs 0.000 claims description 9
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 9
- 229960001936 indinavir Drugs 0.000 claims description 9
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 9
- 229940079322 interferon Drugs 0.000 claims description 9
- 229960001627 lamivudine Drugs 0.000 claims description 9
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 9
- 229960004525 lopinavir Drugs 0.000 claims description 9
- 229960000884 nelfinavir Drugs 0.000 claims description 9
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 9
- 229960000689 nevirapine Drugs 0.000 claims description 9
- 229960001203 stavudine Drugs 0.000 claims description 9
- 229960002555 zidovudine Drugs 0.000 claims description 9
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 9
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960001852 saquinavir Drugs 0.000 claims description 8
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 8
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 6
- 229960005102 foscarnet Drugs 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 5
- 230000002452 interceptive effect Effects 0.000 claims 1
- 229960003521 interferon alfa-2a Drugs 0.000 claims 1
- 229960003507 interferon alfa-2b Drugs 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38340902P | 2002-05-24 | 2002-05-24 | |
| PCT/US2003/016524 WO2003099851A2 (en) | 2002-05-24 | 2003-05-23 | Methods and compositions for inhibiting hiv replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531589A JP2005531589A (ja) | 2005-10-20 |
| JP2005531589A5 true JP2005531589A5 (enExample) | 2010-08-12 |
Family
ID=29584565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508106A Pending JP2005531589A (ja) | 2002-05-24 | 2003-05-23 | Ｈｉｖの複製を阻害するための方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060068389A1 (enExample) |
| EP (1) | EP1523328A4 (enExample) |
| JP (1) | JP2005531589A (enExample) |
| AU (1) | AU2003234637B2 (enExample) |
| CA (1) | CA2487655A1 (enExample) |
| WO (1) | WO2003099851A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071063B2 (en) * | 2008-02-21 | 2011-12-06 | Exxonmobile Research And Engineering Company | Separation of hydrogen from hydrocarbons utilizing zeolitic imidazolate framework materials |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0222385B1 (en) * | 1985-11-13 | 1993-02-03 | Research Development Corporation of Japan | Sex hormones for the treatment of immunodeficiency diseases |
| AU8166191A (en) * | 1990-08-10 | 1992-02-13 | Ortho Pharmaceutical Corporation | Method for treatment of bone wasting diseases |
| US5874225A (en) * | 1993-02-19 | 1999-02-23 | Trustees Of The University Of Pennsylvania | Identification of compounds that modulate HIV-1 vpr protein activity |
| WO1995016705A1 (en) * | 1993-12-15 | 1995-06-22 | The Trustees Of The University Of Pennsylvania | Vpr receptor protein |
| US5639598A (en) * | 1994-05-19 | 1997-06-17 | The Trustees Of The University Of Pennsylvania | Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions |
| US5780220A (en) * | 1994-05-19 | 1998-07-14 | Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting HIV replication |
| US5763190A (en) * | 1994-09-21 | 1998-06-09 | The Trustees Of The University Of Pennsylvania | Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein |
| JPH08239306A (ja) * | 1995-03-03 | 1996-09-17 | Sunstar Inc | 忌避剤 |
| IL120263A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to prevent bone loss-progesterone and estrogen agonists |
| US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| AUPQ127399A0 (en) * | 1999-06-29 | 1999-07-22 | Guangzhou University Of Traditional Chinese Medicine | Compositions and methods for treating or preventing osteoporosis |
-
2003
- 2003-05-23 US US10/515,327 patent/US20060068389A1/en not_active Abandoned
- 2003-05-23 JP JP2004508106A patent/JP2005531589A/ja active Pending
- 2003-05-23 EP EP03729137A patent/EP1523328A4/en not_active Withdrawn
- 2003-05-23 WO PCT/US2003/016524 patent/WO2003099851A2/en not_active Ceased
- 2003-05-23 AU AU2003234637A patent/AU2003234637B2/en not_active Ceased
- 2003-05-23 CA CA002487655A patent/CA2487655A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11773098B2 (en) | Solid forms of a toll-like receptor modulator | |
| Paintsil et al. | Antiviral agents | |
| ES2995458T3 (en) | N4-hydroxycytidine derivative and anti-viral uses related thereto | |
| CN112074506B (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| JP2022044706A (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| JP2023512656A (ja) | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 | |
| JP2017203033A5 (enExample) | ||
| RU2012101881A (ru) | Производные азапептидов | |
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| JP2018512428A5 (enExample) | ||
| WO2021130195A1 (en) | Method of treating virus infection using a tlr7 agonist | |
| CN104244947A (zh) | 用于治疗hcv的方法和组合物 | |
| Burrell et al. | Antiviral chemotherapy | |
| JP2005531589A5 (enExample) | ||
| CN111587107B (zh) | 药物组合物 | |
| JP2005500981A5 (enExample) | ||
| Ekmekyapar et al. | Antiviral Drugs and Their Toxicities | |
| Asmar et al. | Antiviral therapy: Respiratory infections, chornic hepatitis | |
| Shelton | Chutes and ladders in hepatitis C nucleoside drug development | |
| Quan | Pharmacotherapy of hepatitis B infection: a brief review. | |
| HK1239685B (en) | Solid forms of a toll-like receptor modulator | |
| HK1239685A1 (en) | Solid forms of a toll-like receptor modulator | |
| JP2015509980A (ja) | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |